KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells

Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have been widely adopted in colorectal cancer (CRC), but those to predict chemotherapy sensitivity remain poorly defined. We tested our hypothesis that KRAS mutation may be a predictor of oxaliplatin sensit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yu-Lin, Liau, Jau-Yu, Yu, Shan-Chi, Ou, Da-Liang, Lin, Liang-In, Tseng, Li-Hui, Chang, Yih-Leong, Yeh, Kun-Huei, Cheng, Ann-Lii
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508995/
https://www.ncbi.nlm.nih.gov/pubmed/23209813
http://dx.doi.org/10.1371/journal.pone.0050701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508995/
https://www.ncbi.nlm.nih.gov/pubmed/23209813
http://dx.doi.org/10.1371/journal.pone.0050701

Ejemplares similares